ESMO Breast Cancer Virtual Meeting | Conference

Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer

May 17th 2024

Dose reductions of ribociclib plus an NSAI did not decrease the regimen’s efficacy in patients with HR-positive, HER2-negative early breast cancer.

Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer

May 17th 2024

PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.

Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer

May 17th 2024

Adding denosumab to neoadjuvant nab-paclitaxel did not improve 5-year invasive disease-free survival rates in patients with early-stage breast cancer.

Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer

May 16th 2024

Capivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.

T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer

May 16th 2024

Trastuzumab deruxtecan demonstrated superior long-term survival and response rates vs treatment of physician’s choice in HER2-positive breast cancer.

Dato-DXd Reduces High-Grade TRAEs vs Chemo in Pretreated, HR+/HER2– Advanced Breast Cancer

May 16th 2024

Datopotamab deruxtecan was associated with lower rates of high-grade TRAEs vs chemotherapy in the phase 3 TROPION-Breast01 trial.

Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer

May 16th 2024

Vepdegestrant plus palbociclib maintained clinical efficacy and safety in patients with pretreated, advanced ER-positive, HER2-negative breast cancer.

Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC

May 15th 2024

Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.

Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer

May 15th 2024

Olaparib, durvalumab, and fulvestrant produced a 66.7% 24-week PFS rate in patients with endocrine-resistant, ER-positive, HER2-negative breast cancer.

Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC

May 15th 2024

First-line atezolizumab plus sacituzumab govitecan led to responses in PD-L1–positive locally advanced or metastatic triple-negative breast cancer.

Sacituzumab Govitecan Elicits Consistent Safety in Patients With HR+/HER2– Breast Cancer, Regardless of UGT1A1 Status

May 31st 2023

Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the phase 3 TROPiCS-02 trial.

Adjuvant Abemaciclib Provides Survival Benefit in Chinese Breast Cancer Population

May 18th 2023

Abemaciclib plus endocrine therapy delivered sustained survival benefits with a tolerable safety profile when used as adjuvant treatment in Chinese patients with high-risk, hormone receptor–positive, HER2-negative early breast cancer.

Capivasertib Plus Fulvestrant Provides Consistent PFS Benefit in HR+ Advanced Breast Cancer, Across Key Subgroups

May 15th 2023

Capivasertib plus fulvestrant provided a clinically meaningful improvement in progression-free survival over fulvestrant alone in patients with hormone receptor–positive advanced breast cancer, including those who previously received a CDK4/6 inhibitor, chemotherapy in the advanced setting, or had baseline liver metastases.

OP-1250 Plus Palbociclib Demonstrates Activity, Safety in HR+/HER2– Metastatic Breast Cancer

May 14th 2023

The combination of OP-1250 and palbociclib produced a tolerable safety profile and elicited tumor responses and disease stabilization in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

MONALEESA-2 Subgroup Analysis Highlights Survival Benefit With Ribociclib/Letrozole in HR+ Breast Cancer

May 13th 2023

The frontline combination of ribociclib and letrozole significantly prolonged overall survival over letrozole alone in a subset of patients with hormone receptor–positive, HER2-negative advanced breast cancer who had de novo metastatic disease or late recurrence from neoadjuvant therapy, according to data from an exploratory analysis of the phase 3 MONALEESA-2 trial.

Neoadjuvant Atezolizumab/Epirubicin Plus Trastuzumab/Pertuzumab Shows High pCR Rate in Early HER2+ Breast Cancer

May 12th 2023

Preoperative treatment with atezolizumab, epirubicin, trastuzumab, and pertuzumab led to improved rates of pathologic complete response and decreased residual cancer burden compared with trastuzumab, pertuzumab, and chemotherapy alone in patients with early-stage HER2-positive breast cancer, according to findings from the randomized phase 2 ATHENE trial.

Neoadjuvant Atezolizumab Plus Chemotherapy Numerically Improves Survival in Early TNBC

May 12th 2023

The addition of atezolizumab to neoadjuvant chemotherapy generated numerical improvements in event-free survival, disease-free survival, and overall survival compared with chemotherapy plus placebo in patients with early-stage triple-negative breast cancer.

Sacituzumab Govitecan Produces Consistent Clinical Outcomes in mTNBC, Irrespective of Neutropenia and Diarrhea AEs

May 12th 2023

Sacituzumab govitecan-hziy produced comparable efficacy outcomes for patients with metastatic triple-negative breast cancer who had a higher incidence of grade 2 or 3 diarrhea and neutropenia vs patients in the overall population, according to a post hoc analysis of the phase 3 ASCENT trial presented at the 2023 ESMO Breast Cancer Annual Congress.

ER-low Expressors Experience Benefit With Trastuzumab Deruxtecan in DESTINY-Breast04 Subgroup Analysis

May 12th 2023

Fam-trastuzumab deruxtecan-nxki was associated with better efficacy outcomes compared with treatment of physician’s choice in patients with HER2-low, estrogen receptor-low metastatic breast cancer, according to findings from a subgroup analysis of the phase 3 DESTINY-Breast04 study.

Post-Hoc Analysis Shows Olaparib Maintains PFS Benefit in gBRCA+ HER2– Metastatic Breast Cancer, Irrespective of ER Expression

May 11th 2023

Olaparib provided consistent clinical benefit in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, irrespective of estrogen receptor expression level.